Vision improvement maintained in LHON at 4 years after single gene therapy injection
Lumevoq demonstrated continued vision improvement in Leber hereditary optic neuropathy 4 years after a single gene therapy injection, according to a press release from GenSight Biologics.
Participants with Leber hereditary optic neuropathy (LHON) experienced a mean improvement of 22.5 letters of best corrected visual acuity in the study eye that received Lumevoq (GS010; lenadogene nolparvovec) at 4 years compared with their lowest point, while sham-treated eyes experienced an improvement of 20.5 letters, according to the release. Results come from RESTORE, a long-term follow-up study investigating participants from the phase 3 RESCUE and REVERSE pivotal trials.
“The body of evidence we have now accumulated is without doubt good news for patients needing an urgent solution for their brutal blinding condition, and consequently we are continuing to work vigorously with the relevant authorities to bring regulatory review process to a successful conclusion,” Bernard Gilly, co-founder and CEO of GenSight Biologics, said in the release.
The were no serious adverse events recorded in Lumevoq-treated eyes, and there were no systemic serious adverse events or discontinuations related to the treatment, according to the release.
Read more about